Your session is about to expire
← Back to Search
Combined Therapy for Pancreatic Cancer
Study Summary
This trial is testing to see if the combination of these interventions can effectively treat pancreatic tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 32 Patients • NCT01839799Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 18 years.I am allergic to certain chemotherapy drugs or losartan.I had major surgery less than 4 weeks ago and haven't fully recovered.My pancreatic cancer is confirmed and may be operable or advanced but not spread.I am not currently on ACE or ARB therapy for high blood pressure or kidney protection.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.Your blood pressure is higher than 100 mm Hg when the study starts.I have been on a stable dose of dexamethasone (2 mg or less) for at least 7 days.You have a positive test for hepatitis B or hepatitis C, showing that you have an ongoing infection.You have had a serious allergic reaction to any monoclonal antibody in the past.My organ and bone marrow functions are normal.I have or had lung inflammation not caused by an infection.You have an autoimmune disease that is not on the approved list.I do not have uncontrolled seizures, significant brain disorders, or severe mental health issues.I have an active tuberculosis infection.I am fully active and can carry on all my pre-disease activities without restriction.I have received treatments like chemotherapy for my pancreatic tumor.I have issues with my digestive system that affect how I absorb food.I am not taking cimetidine, as it can affect my cancer treatment.I have a bleeding disorder that is not under control.I haven't taken high-dose steroids or immunosuppressants in the last 2 weeks.I have not received a live vaccine in the last 30 days.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery
- Group 2: FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur
- Group 3: FOLFIRINOX: SBRT: Surgery
- Group 4: FOLFIRINOX+Losartan:SBRT+Losartan:Surgery
Frequently Asked Questions
What adverse effects have been associated with FOLFIRINOX usage?
"FOLFIRINOX is believed to be moderately safe, as evidenced by its score of 2. That being said, there isn't any proof that it can effectively treat the targeted condition at this time."
What therapeutic purposes is FOLFIRINOX most commonly used for?
"FOLFIRINOX is widely employed to treat metastatic gastroesophageal junction adenocarcinoma. It has also been utilized successfully in cases of metastatic gastric adenocarcinoma, renal cell carcinoma, and complete resection."
In what exact venues is this experiment taking place?
"This trial is being conducted across a variety of medical institutions, such as Beth Israel Deaconess Medical Center in Aurora, Massachusetts General Hospital in Newton and Brigham and Women's Hospital in Houston. There are 10 locations running this clinical study overall."
Are any more participants being sought for this research endeavor?
"The clinicaltrials.gov records show that this trial, which was initially posted on August 10th 2018 and last updated September 7th 2022, is no longer actively recruiting candidates. However, there are over 1400 other medical studies seeking participants currently."
Is there a cap on the number of participants in this clinical trial?
"As of the last update on September 7th 2022, new participants are no longer being accepted. The study was originally published August 10th 2018. Currently, 697 medical trials related to malignant neoplasm of pancreas and an additional 746 studies for FOLFIRINOX are actively recruiting patients."
What other empirical experiments have been conducted regarding FOLFIRINOX?
"At the current moment, 746 clinical trials are underway related to FOLFIRINOX. Of these studies, 84 have advanced to Phase 3 of research. The majority of examinations for this therapy are being conducted in Zurich, BE though 40759 other sites also provide access to such tests."
Share this study with friends
Copy Link
Messenger